Tetramer Shop marks the fifth acquisition for
Tetramer Shop was founded by Søren Jakobsen, Professors Sine Hadrup and Sunil Kumar from
“Tetramer Shop will enable our customers to accelerate the development of TCR-based therapeutics and diagnostics that are critical to immunology, and we are thrilled to have them join forces with us,” said
Upcoming products detailed at Xperience 2021 followed their initial reveal last month at the annual
- Low Throughput (LT) Single Cell Gene Expression solution - Enabling proof of concept before scaling, this kit will democratize single-cell sequencing by lowering startup costs by up to 60 percent. It is expected to ship in the first half of 2021.
- CellPlex Kit - Cell Multiplexing allows for increased sample and cell throughput as multiple samples and higher cell loads can be loaded into each channel. Seen as a way to lower costs for labs and increase adoption of the Chromium platform, it is expected to arrive in Q1 2021.
- Chromium X - This next generation single-cell instrument will make experiments of up to one million cells routine. It is expected to ship in the second half of 2021.
- Fixed RNA Profiling Kit - Offering whole transcriptome and targeted based readouts, this product addresses sample preparation challenges by preserving cell/sample integrity and the need to process samples in batches and transport samples. The company expects it to launch in the second half of 2021.
- Barcode Enabled Antigen Mapping (BEAM) Solution - Provides an end-to-end solution for the high-throughput discovery of antibodies and T cell receptors against multiple antigens in a week. The product, targeted at biotech and pharmaceutical companies, is expected to launch in the first half of 2022.
Continuing its commitment to leading the way in spatial analysis, 10x also shared closer looks at three new capabilities that will be coming to its Visium platform over the next 18 months:
- Visium for FFPE - Removing the need for an expensive dedicated instrument, Visium for FFPE will allow researchers to measure gene expression across an entire tissue that has been formalin-fixed paraffin-embedded without having to pre-select regions of interest. It is the first technology to enable true discovery in FFPE samples, delivering the full transcriptome across the entire tissue with sensitivity on par with analyzing fresh tissues with standard Visium. It is expected to ship in Q2 of 2021.
- Visium Highly Multiplexed Protein - This new offering enables high-plexy spatial multiomic readouts on the same tissue section with one workflow for a next-gen sequencing readout. It is expected to be available starting the second half of 2021.
- Visium CytAssist - A benchtop instrument intended to facilitate the simple and rapid capture of fresh or archived tissue sections for analysis, CytAssist will enable users to stain and pre-screen tissue sections mounted on standard microscopy slides prior to gene or protein expression analysis with Visium assays. It is expected to arrive in the first half of 2022.
- Visium HD - This revolutionary product will get spatial transcriptomics to its ultimate goal of single-cell resolution with 400x times the resolution of the current Visium solution for both FFPE and fresh frozen samples with whole transcriptome, targeted, and highly multiplexed protein assays. It is expected to be available in the first half of 2022.
Finally, 10x announced the US launch of its 10x Genomics Cloud Analysis, a fast, easy-to-use, and scalable platform for data analysis to all of its customers which offers a standard set of analyses at no additional cost for every sample purchased. The 10x Cloud will enable new users to get started more rapidly on their experiments and allow advanced users to scale to larger and more complex ones. The company also outlined its roadmap to bring new applications, new visualizations, and support for additional regions around the globe.
“Xperience 2021 is a fantastic way for us to share a view of our future roadmap in a way we’ve never done before,” continued Hindson. “The products and capabilities we showcased today represent some of our most innovative work to date, and we hope they will empower scientists to make new discoveries in biology.”
To learn more about products showcased at Xperience 2021, please visit http://www.10xgenomics.com/xperience2021. The event will also be hosted on
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding
Disclosure Information
Contacts
Media:
media@10xgenomics.com
Investors:
investors@10xgenomics.com
Source:
2021 GlobeNewswire, Inc., source